Privia Health Group, Inc.
NASDAQ:PRVAMedical - Healthcare Information Services
+$0.15 today
- Market cap
- $3.14B
- Beta
- 0.87
- P/E (TTM)
- 134.4
- EPS (TTM)
- $0.18
Volume 2.38M
Average 0.95M
PRVA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Privia Health Group, Inc.NASDAQ: PRVA
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $3.36M rose 29.9% year over year, behind the +48.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.
Context
- Depreciation & amortization amounted to 0.5% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +29.9% toward the trailing-twelve-month pace of +48.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 9.91M USD
- Year-over-year change
- +36.3%
- 4-year CAGR
- +41.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.91M | +36.3% |
| FY2024 | 2024-12-31 | 7.27M | +11.3% |
| FY2023 | 2023-12-31 | 6.53M | +42.9% |
| FY2022 | 2022-12-31 | 4.57M | +85.5% |
| FY2021 | 2021-12-31 | 2.46M | — |
Depreciation & Amortization vs competitors
How PRVA compares with its peers on the latest reported figures
- PRVA's LTM Jun 2026 depreciation & amortization of $12.06M is the 9th highest of the 10 companies compared; the peer median is $34.65M.
- Its year-over-year change of +48.7% is the 2nd highest of 10, against a peer median of +13.1%.
- Depreciation & amortization amounts to 0.5% of revenue for PRVA, versus a peer median of 7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $233.19M | +6.2% | +20.0% | 9.3% | |
| LTM Mar 2026 | $118.75M | +4.1% | +8.7% | 6.3% | |
| LTM Mar 2026 | $54.38M | +83.2% | +37.6% | 1.5% | |
| LTM Mar 2026 | $50.3M | +16.4% | -0.7% | 16.6% | |
| LTM Apr 2026 | $34.65M | +22.0% | +3.0% | 7.0% | |
| LTM Mar 2026 | $33.82M | +3.9% | +9.1% | 14.2% | |
| LTM Mar 2026 | $28.51M | +11.8% | +27.6% | 0.5% | |
| LTM Mar 2026 | $17.82M | +30.0% | +4.2% | 14.4% | |
| LTM Jun 2026 | $12.06M | +48.7% | +29.4% | 0.5% | |
| LTM Mar 2026 | $5.67M | +13.1% | +8.2% | 2.0% | |
| Peer median (excluding PRVA) | $34.65M | +13.1% | +8.7% | 7.0% | |
Competitors are the stored peer set for PRVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 966.22M | 1.36B | 1.66B | 1.74B | 2.12B |
| Cost of Revenue | 902.56M | 1.22B | 1.5B | 1.56B | 1.91B |
| Gross Profit | 63.66M | 134.78M | 161.5M | 176.85M | 209.43M |
| Gross Margin | 6.6% | 9.9% | 9.7% | 10.2% | 9.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 278.63M | 149.33M | 134.32M | 152.6M | 165.29M |
| Operating Expenses | 281.1M | 153.9M | 140.85M | 159.87M | 175.2M |
| Depreciation & Amortization | 2.46M | 4.57M | 6.53M | 7.27M | 9.91M |
| EBITDA | (214.97M) | (14.01M) | 35.55M | 35.14M | 53.85M |
| EBITDA Margin | -22.2% | -1.0% | 2.1% | 2.0% | 2.5% |
| Operating Income | (217.44M) | (19.12M) | 20.65M | 16.98M | 34.24M |
| Operating Margin | -22.5% | -1.4% | 1.2% | 1.0% | 1.6% |
| Interest Income | 0 | 542K | 8.37M | 10.89M | 9.7M |
| Interest Expense | 1.07M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.07M) | 542K | 8.37M | 10.89M | 9.7M |
| Income Before Tax | (218.51M) | (18.58M) | 29.02M | 27.87M | 43.94M |
| Pre-Tax Margin | -22.6% | -1.4% | 1.8% | 1.6% | 2.1% |
| Income Tax Expense | (27.86M) | (6.52M) | 7.99M | 10.83M | 14.21M |
| Net Income | (188.23M) | (8.59M) | 23.08M | 14.39M | 22.92M |
| Net Margin | -19.5% | -0.6% | 1.4% | 0.8% | 1.1% |
| EPS (Basic) | (1.77) | (0.08) | 0.20 | 0.12 | 0.19 |
| EPS (Diluted) | (1.77) | (0.08) | 0.19 | 0.11 | 0.18 |
| Weighted Avg Shares | 107.84M | 110.7M | 116.73M | 119.4M | 122.18M |
| Weighted Avg Shares (Diluted) | 107.84M | 110.7M | 124.69M | 125.61M | 128.89M |
Privia Health Group, Inc.
NASDAQ:PRVA
Intrinsic Alpha fair value
Locked
Current Price
$24.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.